Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment

Inclusion Criteria: 1. Patient with a characterized depressive episode defined according to DSM-5 (diagnostic and statistical manual of mental disorders) criteria; 2. Patient between the ages of 18 and 65 years; 3. Inpatient with an inadequate response to two prior well-conducted antidepressant treatments (Hamilton 17-item scale \[HAMD-17\] score at inclusion≥ 18) ; 4. Patient with written informed consent to participate in the study; 5. Patient enrolled in or receiving social security benefits. Exclusion Criteria: 1. Patient with endocrinopathy ; 2. Patient with a contraindication to neuroendocrine testing (hypersensitivity to the active substance or to one of the excipients); 3. Patient with a contraindication to rTMS: * cochlear implant, * cardiac pacemaker, * metal clips, stents or other electronic implants within one meter of the stimulation coil, * intracranial hypertension, * poorly balanced comitiality, * in the case of well-balanced comitiality, a neurological consultation with electroencephalogram (EEG) is planned before including the patient; 4. Patient previously treated with monoamine oxidase inhibitor (MAOI) antidepressant or lithium salts (within 6 months prior to inclusion); 5. Pregnant or lactating patient; 6. Patient under court protection or deprived of liberty; 7. Patient under guardianship/guardianship.